215 related articles for article (PubMed ID: 35860287)
1. Cancer Treatment-Induced Bone Loss: Role of Denosumab in Non-Metastatic Breast Cancer.
Dhabhar B
Breast Cancer (Dove Med Press); 2022; 14():163-173. PubMed ID: 35860287
[TBL] [Abstract][Full Text] [Related]
2. Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.
Nakatsukasa K; Koyama H; Ouchi Y; Ono H; Sakaguchi K; Matsuda T; Kato M; Ishikawa T; Yamada K; Yoshimura M; Koizumi K; Sakurai T; Shigematsu H; Takahashi S; Taira S; Suzuki M; Narui K; Niikura N; Hasegawa Y; Miura D; Konishi E; Taguchi T;
Breast Cancer; 2019 Jan; 26(1):106-112. PubMed ID: 30054855
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.
Ellis GK; Bone HG; Chlebowski R; Paul D; Spadafora S; Smith J; Fan M; Jun S
J Clin Oncol; 2008 Oct; 26(30):4875-82. PubMed ID: 18725648
[TBL] [Abstract][Full Text] [Related]
4. Effect of antiresorptive therapy on aromatase inhibitor induced bone loss in postmenopausal women with early-stage breast cancer: A systematic review and meta-analysis of randomized controlled trials.
Bassatne A; Bou Khalil A; Chakhtoura M; Arabi A; Van Poznak C; El-Hajj Fuleihan G
Metabolism; 2022 Mar; 128():154962. PubMed ID: 34958816
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Gnant M; Pfeiler G; Steger GG; Egle D; Greil R; Fitzal F; Wette V; Balic M; Haslbauer F; Melbinger-Zeinitzer E; Bjelic-Radisic V; Jakesz R; Marth C; Sevelda P; Mlineritsch B; Exner R; Fesl C; Frantal S; Singer CF;
Lancet Oncol; 2019 Mar; 20(3):339-351. PubMed ID: 30795951
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Options for the Management of Aromatase Inhibitor- Associated Bone Loss.
Gaudio A; Xourafa A; Rapisarda R; Castellino P
Endocr Metab Immune Disord Drug Targets; 2022; 22(3):259-273. PubMed ID: 34370654
[TBL] [Abstract][Full Text] [Related]
7. Updated guidance on the management of cancer treatment-induced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer.
Waqas K; Lima Ferreira J; Tsourdi E; Body JJ; Hadji P; Zillikens MC
J Bone Oncol; 2021 Jun; 28():100355. PubMed ID: 33948427
[TBL] [Abstract][Full Text] [Related]
8. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
Brufsky A
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
[TBL] [Abstract][Full Text] [Related]
9. Effect of denosumab on bone mineral density in Japanese women with osteopenia treated with aromatase inhibitors for breast cancer: subgroup analyses of a Phase II study.
Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
Ther Clin Risk Manag; 2018; 14():1213-1218. PubMed ID: 30022834
[TBL] [Abstract][Full Text] [Related]
10. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
Gnant M; Pfeiler G; Dubsky PC; Hubalek M; Greil R; Jakesz R; Wette V; Balic M; Haslbauer F; Melbinger E; Bjelic-Radisic V; Artner-Matuschek S; Fitzal F; Marth C; Sevelda P; Mlineritsch B; Steger GG; Manfreda D; Exner R; Egle D; Bergh J; Kainberger F; Talbot S; Warner D; Fesl C; Singer CF;
Lancet; 2015 Aug; 386(9992):433-43. PubMed ID: 26040499
[TBL] [Abstract][Full Text] [Related]
12. Bone modifying agents for bone loss in patients with aromatase inhibitor as adjuvant treatment for breast cancer; insights from a network meta-analysis.
Miyashita H; Satoi S; Kuno T; Cruz C; Malamud S; Kim SM
Breast Cancer Res Treat; 2020 Jun; 181(2):279-289. PubMed ID: 32318956
[TBL] [Abstract][Full Text] [Related]
13. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study.
Ellis GK; Bone HG; Chlebowski R; Paul D; Spadafora S; Fan M; Kim D
Breast Cancer Res Treat; 2009 Nov; 118(1):81-7. PubMed ID: 19308727
[TBL] [Abstract][Full Text] [Related]
14. Skeletal health in breast cancer survivors.
Bruyère O; Bergmann P; Cavalier E; Gielen E; Goemaere S; Kaufman JM; Rozenberg S; Body JJ
Maturitas; 2017 Nov; 105():78-82. PubMed ID: 28838807
[TBL] [Abstract][Full Text] [Related]
15. Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab.
Lipton A; Smith MR; Ellis GK; Goessl C
Clin Med Insights Oncol; 2012; 6():287-303. PubMed ID: 22933844
[TBL] [Abstract][Full Text] [Related]
16. Denosumab vs. zoledronic acid treatment in post-menopausal breast cancer: a 2-year prospective observational study.
Buch-Larsen K; Jørgensen NR; Jensen LT; Andersson M; Schwarz P
Scand J Clin Lab Invest; 2021 Oct; 81(6):425-431. PubMed ID: 34120544
[TBL] [Abstract][Full Text] [Related]
17. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.
Rizzoli R; Body JJ; DeCensi A; Reginster JY; Piscitelli P; Brandi ML;
Osteoporos Int; 2012 Nov; 23(11):2567-76. PubMed ID: 22270857
[TBL] [Abstract][Full Text] [Related]
18. The effect of denosumab in breast cancer patients receiving adjuvant aromatase inhibitors: 36-month results.
Ouchi Y; Nakatsukasa K; Sakaguchi K; Morita M; Koyama H; Matsuda T; Kato M; Konishi E; Ono H; Taguchi T
J Bone Miner Metab; 2021 Mar; 39(2):224-229. PubMed ID: 32889575
[TBL] [Abstract][Full Text] [Related]
19. Denosumab: in cancer treatment-induced bone loss.
Muir VJ; Scott LJ
BioDrugs; 2010 Dec; 24(6):379-86. PubMed ID: 21043545
[TBL] [Abstract][Full Text] [Related]
20. Management of bone loss in postmenopausal breast cancer patients treated with aromatase inhibitors.
Cepa M; Vaz C
Acta Reumatol Port; 2015; 40(4):323-30. PubMed ID: 26922195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
